Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by progressive muscle weakness and degeneration. It primarily affects motor neurons in the spinal cord, leading to a loss of muscle control and mobility difficulties. SMA is a complex condition with various forms, each differing in severity and age of onset. From infants to adults, understanding the different types of SMA, their causes, symptoms, and available treatment options is essential for patients, caregivers, and healthcare providers.

At the core of SMA lies a genetic mutation impacting the survival of motor neuron (SMN) protein, which is vital for the proper functioning of motor neurons. Without sufficient SMN protein, these neurons deteriorate, resulting in muscle weakening and atrophy. The most common cause is a mutation in the SMN1 gene located on chromosome 5. However, other less common forms of SMA are caused by mutations in genes outside chromosome 5, which makes diagnosis and treatment more complex.

Types of Spinal Muscular Atrophy

• Type 1 (Werdnig-Hoffmann disease): Usually diagnosed in infants within the first six months of life, leading to severe muscle weakness, failure to develop motor skills, and often respiratory failure. Without intervention, it can be life-threatening.
• Type 2: Usually appears in children between 6 and 18 months. Children with type 2 can sit but often cannot walk unaided. Muscle weakness is moderate to severe, affecting mobility and respiratory functions.
• Type 3 (Kugelberg-Welander disease): Often begins in late childhood or adolescence. Individuals may achieve walking, but muscle weakness progresses over time, potentially leading to wheelchair dependence.
• Type 4: Adult-onset SMA, characterized by mild symptoms that develop later in life. The progression is slower, and mobility may be preserved longer.

Major Symptoms and Signs

The hallmark of SMA is muscle weakness, especially in proximal muscles, which are those closest to the body's core. These include the shoulders, hips, thighs, and upper back. As the disease advances, weakened muscles can cause deformities such as spinal curvature (scoliosis), difficulty swallowing (dysphagia), and breathing complications due to weakened respiratory muscles.

Importantly, SMA specifically affects motor neurons, meaning sensory, cognitive, and emotional functions remain unaffected. Patients retain normal sensation, intelligence, and emotional processing abilities, which highlights the disease's specific impact on muscle control and movement.

Genetic Basis and Inheritance Patterns

SMA is inherited in an autosomal recessive pattern. This means that a person must inherit two copies of the mutated SMN1 gene—one from each parent—to develop the disorder. Typically, parents are carriers, each possessing one mutated copy of the gene but showing no symptoms. When two carriers have a child together, there is a 25% chance that the child will inherit SMA. Occasionally, a person with SMA may inherit one mutated gene from a parent and then acquire a new mutation in the other gene during gamete formation or early embryonic development. This spontaneous mutation can lead to SMA even when parents are not carriers.

Advancements in Diagnosis and Treatment

Diagnosis of SMA involves genetic testing to identify mutations in the SMN1 gene. Electromyography (EMG), muscle biopsies, and other electrophysiological tests may assist in confirming the diagnosis. Early detection is crucial to optimize treatment outcomes.

In recent years, significant advances have been made in the development of therapies targeting SMA. Approaches include gene therapy, such as the use of viral vectors to deliver functional copies of the defective gene, and medications that increase the production of SMN protein, like nusinersen (Spinraza), risdiplam (Evrysdi), and onasemnogene abeparvovec (Zolgensma). These treatments can improve muscle strength, delay disease progression, and in some cases, significantly increase lifespan, especially when administered early in the disease course.

Living with SMA

While there is currently no cure for SMA, comprehensive management includes physical therapy, respiratory support, nutritional support, and assistive devices to enhance quality of life. Multidisciplinary care teams comprising neurologists, pulmonologists, physiotherapists, and nutritionists play a vital role in treatment planning and ongoing support.

Research continues to explore innovative therapies and better understanding of the disease mechanisms. Support networks, patient advocacy groups, and clinical trials provide hope for new treatments and improved management strategies in the future.